Outlook Therapeutics (OTLK) joint holders report 4.99% stake after SPA

Rhea-AI Filing Summary

Outlook Therapeutics, Inc. Schedule 13G discloses that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC (the Reporting Persons) are filing jointly to report beneficial ownership tied to a Securities Purchase Agreement dated April 22, 2026. The Reporting Persons may be deemed to beneficially own 5,990,447 shares of Common Stock, representing 4.99% of the class based on 103,067,190 shares outstanding (prior to the SPA). The filing describes additional shares issuable upon exercise of warrants (including 6,451,613 shares under Intracoastal Warrant 1 and warrants totaling 2,000,000 or adjusted figures subject to blocker provisions) and explains blocker provisions that prevent exercises that would push ownership above 4.99%.

Insights

Corporate Governance Analyst

Joint 13G reports a 4.99% stake with blocker clauses limiting further immediate exercise.

The filing shows a coordinated beneficial position by two individuals and a related LLC tied to a recent SPA effective April 22, 2026. It documents shares issuable on exercise of two warrants and explicit blocker provisions that cap exercise rights at 4.99%.

This is primarily an ownership disclosure; material change in control is not indicated. Subsequent filings may disclose whether and when warrants become exercisable and any stockholder approvals required for additional issuances.

Capital Markets Specialist

Ownership sits at the 4.99% reporting threshold after a SPA close; further dilution is gated by warrant terms.

The report ties the reported ownership to 103,067,190 shares outstanding prior to the SPA and to shares to be issued at closing. It details two warrants (one with 6,451,613 underlying shares and another with up to 2,000,000 or adjusted amounts) that include blocker provisions and exercise conditions.

Key items to watch in future filings: the effective date of any stockholder approval or charter amendment that would enable additional warrant exercises and any changes to the outstanding share base affecting the 4.99% threshold.

Key Figures

Beneficial ownership reported: 5,990,447 shares Percent of class: 4.99% Shares outstanding used in calc: 103,067,190 shares +2 more

5 metrics

Beneficial ownership reported 5,990,447 shares as of close of business April 24, 2026

Percent of class 4.99% based on 103,067,190 shares outstanding prior to the SPA

Shares outstanding used in calc 103,067,190 shares outstanding prior to the SPA (reported to Reporting Persons)

Intracoastal Warrant 1 underlying 6,451,613 shares shares issuable upon exercise of Intracoastal Warrant 1 (exercise conditions apply)

Intracoastal Warrant 2 underlying (not fully exercisable) 2,000,000 shares shares issuable upon exercise of Intracoastal Warrant 2 (blocker provisions limit exercise)

Key Terms

blocker provision, Securities Purchase Agreement (SPA), beneficial ownership, issuable upon exercise

4 terms

blocker provision regulatory

"contains a blocker provision under which the holder thereof does not have the right to exercise"

Securities Purchase Agreement (SPA) financial

"Immediately following the execution of the Securities Purchase Agreement with the Issuer on April 22, 2026 (the "SPA")"

A securities purchase agreement is a legally binding contract that spells out the sale of shares or other securities, listing what is being sold, the price, how and when ownership changes hands, and any checks or approvals required before closing. Think of it as a detailed bill of sale plus rulebook: it sets buyer and seller promises, protections and conditions, so investors can assess who bears risk, when the deal will complete, and how the purchase may affect ownership and value.

beneficial ownership regulatory

"may have been deemed to have beneficial ownership of 6,451,613 shares of Common Stock"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

issuable upon exercise financial

"shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 05:17 PM Learn about SEC filing dates

FAQ

What stake does the Schedule 13G show for Outlook Therapeutics (OTLK)?

The Schedule 13G reports beneficial ownership of 5,990,447 shares, equal to 4.99%. This uses a base of 103,067,190 shares outstanding prior to the SPA and counts shares issued at the SPA closing in the ownership calculation.

Who are the Reporting Persons on the Schedule 13G for OTLK?

The filing is a joint report by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. The document states they filed jointly and provides their principal business addresses and citizenship information.

Do the Reporting Persons hold warrants that could increase their ownership in OTLK?

Yes. The filing references Intracoastal Warrant 1 (6,451,613 shares underlying) and Intracoastal Warrant 2 (up to 2,000,000 or adjusted amounts). Both warrants contain blocker provisions limiting exercise to avoid beneficial ownership above 4.99%.

What limits exercise of the warrants reported in the filing?

Each warrant contains a blocker provision that prevents exercise to the extent it would result in beneficial ownership above 4.99%. One warrant is also subject to conditions such as stockholder approval or an amendment increasing authorized shares before it becomes exercisable.

What outstanding share base does the filing use to calculate the 4.99% figure?

The calculation is based on 103,067,190 shares of Common Stock outstanding prior to the SPA. The filing explains the percentage using that base plus shares issued at the SPA closing.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Outlook Therapeutics, Inc

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

69012T305

(CUSIP Number)

04/22/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 69012T305

1

Names of Reporting Persons

Mitchell P. Kopin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,990,447.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,590,447.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,990,447.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 69012T305

1

Names of Reporting Persons

Daniel B. Asher

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,990,447.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,590,447.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,990,447.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 69012T305

1

Names of Reporting Persons

Intracoastal Capital LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,990,447.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,590,447.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,990,447.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Outlook Therapeutics, Inc
(b)	Address of issuer's principal executive offices: 111 S. Wood Avenue, Unit #100, Iselin, New Jersey 08830
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
(c)	Citizenship: Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)	Title of class of securities: Common Stock, par value $0.01 per share
(e)	CUSIP Number(s): 69012T305
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on April 22, 2026 (the "SPA") (as disclosed in the Form 424B4 prospectus filed by the Issuer with the Securities and Exchange Commission on April 23, 2026), each of the Reporting Persons may have been deemed to have beneficial ownership of 6,451,613 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such shares of Common Stock represent beneficial ownership of approximately 5.9% of the Common Stock, based on (1) 103,067,190 shares of Common Stock outstanding prior to the execution of the SPA, as reported to the Reporting Persons by the Issuer, plus (2) 6,451,613 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes (I) 6,451,613 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 1") because Intracoastal Warrant 1 is not exercisable until the later of (a) the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (b) the effective date of an amendment to the Issuer's certificate of incorporation to increase its authorized shares of Common Stock (and Intracoastal Warrant 1 also contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock) and (II) 2,000,000 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 2") because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions (and assuming Intracoastal Warrant 1 was currently exercisable), each of the Reporting Persons may have been deemed to have beneficial ownership of 14,903,226 shares of Common Stock. (ii) As of the close of business on April 24, 2026, each of the Reporting Persons may have been deemed to have beneficial ownership of 5,990,447 shares of Common Stock, which consisted of (i) 5,137,613 shares of Common Stock held by Intracoastal and (ii) 852,834 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock represent beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 103,067,190 shares of Common Stock outstanding prior to the execution of the SPA, as reported to the Reporting Persons by the Issuer, plus (2) 16,129,033 shares of Common Stock issued at the closing of the transaction contemplated by the SPA and (3) 852,834 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes (I) 6,451,613 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 is not exercisable until the later of (a) the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (b) the effective date of an amendment to the Issuer's certificate of incorporation to increase its authorized shares of Common Stock (and Intracoastal Warrant 1 also contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock) and (II) 1,147,166 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 2") because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions (and assuming Intracoastal Warrant 1 was currently exercisable), each of the Reporting Persons may have been deemed to have beneficial ownership of 13,589,226 shares of Common Stock.
(b)	Percent of class: 4.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 5,990,447
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 5,590,447
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mitchell P. Kopin

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin
Date:	04/24/2026

Daniel B. Asher

Signature:	/s/ Daniel B. Asher
Name/Title:	Daniel B. Asher
Date:	04/24/2026

Intracoastal Capital LLC

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin, Manager
Date:	04/24/2026

Exhibit Information

Exhibit 1 - Joint Filing Agreement